Envoy Medical posts Q2 loss, submits first FDA PMA module for Acclaim implant

Envoy Medical, Inc.

2026-Q2 EPS reported -$0.15 revenue$90,000

Q2 2026 net loss of $7.27M ($0.07/share) vs $6.94M ($0.32/share) in Q2 2025; revenue only $51K.
Submitted first of four modular PMA modules to FDA for Acclaim cochlear implant; final module targeted Q2 2027.
12-month Stage 1 data: mean CNC word score 53.2% vs 15.2% baseline (38.0 pp gain), up from 24.0 pp at 6 months.
R&D spending rose to $3.13M from $2.49M on clinical trial and PMA work; cash ~$19.7M at June 30.
Terminated $15M ATM equity facility; 4 patents granted in Australia and Europe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.